About
Skyhawktx develops orally-administered small molecule drugs that modulate RNA splicing to treat neurodegenerative diseases, with a pipeline focused on Huntington's disease and other rare neurological conditions.
Explore Skyhawktx's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.